A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma
Status:
Recruiting
Trial end date:
2027-03-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if the combination of rituximab and ibrutinib can help
people with marginal zone lymphoma who have not received treatment in the past. The study
will also compare the combination of rituximab and ibrutinib with the combination of
rituximab and placebo to see which combination works better.